# ARCADIA (NCT03824691)

> hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

No report yet. It can be ordered.

- Drugs tested: cabozantinib plus durvalumab
- Indication: advanced bladder carcinoma after platinum chemotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03824691
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Conditions: Bladder Carcinoma
- Interventions: Cabozantinib; Durvalumab
- Enrollment: 122
- Primary outcome: The primary endpoint of the study will be overall survival (OS).

## Indexed commentary on ARCADIA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=arcadia-nct03824691